{"created":"2023-06-19T11:44:05.574311+00:00","id":13890,"links":{},"metadata":{"_buckets":{"deposit":"c0a7d71b-7910-43fc-834d-f4aaa8c4bafc"},"_deposit":{"created_by":15,"id":"13890","owners":[15],"pid":{"revision_id":0,"type":"depid","value":"13890"},"status":"published"},"_oai":{"id":"oai:mie-u.repo.nii.ac.jp:00013890","sets":["631:636:1692684776404"]},"author_link":["45503","45504"],"item_8_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019-05-27","bibliographicIssueDateType":"Issued"}}]},"item_8_description_14":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"application/pdf","subitem_description_type":"Other"}]},"item_8_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"本研究では、ICIの作用部位であるエフェクターT細胞、NK細胞の特性変化について、末梢血を試料として治療効果や副作用との関連性を評価した。ROC解析より、好中球数およびCD28陽性CD8陽性T細胞数は、non-PDの予測率がそれぞれ81.8%、72.7%であった。ICI治療早期における好中球数やCD28陽性CD8陽性T細胞は、ICI治療を予測するバイオマーカーとなる可能性がある。","subitem_description_type":"Abstract"},{"subitem_description":"This study was performed to investigate the association of host factors including peripheral blood cell characteristics with the PD-1/PD-L1 therapy. A total of 20 patients were enrolled. The number of patients administrated pembrolizumab, nivolumab, and atezolizumab was 12, 7 and 1, respectively. Twelve patients were diagnosed as progressive disease (PD), and 8 were non-PD. All 6 female patients were diagnosed as PD. In the blood sample obtained within 3 weeks from the immune therapy, significantly high CD28 positive CD8+ T lymphocyte counts and low neutrophil counts were observed in the non-PD patients compared with the PD patients. Meanwhile, the distribution of tumor PD-L1 levels, clinical stage of NSCLC, and other immune markers investigated in the non-PD patients were comparable with the PD patients. CD28 positive CD8+ T lymphocyte and neutrophil counts were considered to be possible biomarkers related to the efficacy of PD-1/PD-L1 therapy.","subitem_description_type":"Abstract"}]},"item_8_description_5":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"2016年度～2018年度科学研究費補助金(基盤研究(C))研究成果報告書","subitem_description_type":"Other"}]},"item_8_description_64":{"attribute_name":"科研費番号","attribute_value_mlt":[{"subitem_description":"16K08369","subitem_description_type":"Other"}]},"item_8_publisher_30":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"三重大学"}]},"item_8_text_31":{"attribute_name":"出版者（ヨミ）","attribute_value_mlt":[{"subitem_text_value":"ミエダイガク"}]},"item_8_text_65":{"attribute_name":"資源タイプ（三重大）","attribute_value_mlt":[{"subitem_text_value":"Kaken / 科研費報告書"}]},"item_8_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"岩本, 卓也","creatorNameLang":"ja"},{"creatorName":"イワモト, タクヤ","creatorNameLang":"ja-Kana"},{"creatorName":"Iwamoto, Takuya","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"奥田, 真弘","creatorNameLang":"ja"},{"creatorName":"オクダ, マサヒロ","creatorNameLang":"ja-Kana"},{"creatorName":"OKUDA, masahiro","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-11-16"}],"displaytype":"detail","filename":"2020RP0048.pdf","filesize":[{"value":"250.6 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"2020RP0048","url":"https://mie-u.repo.nii.ac.jp/record/13890/files/2020RP0048.pdf"},"version_id":"9cbd959f-547f-43e8-affe-aa6edf98b3f3"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"免疫チェックポイント阻害薬","subitem_subject_scheme":"Other"},{"subitem_subject":"バイオマーカー","subitem_subject_scheme":"Other"},{"subitem_subject":"がん化学療法","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"免疫チェックポイント阻害薬のPK/PD評価系構築と個別化治療への応用","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"免疫チェックポイント阻害薬のPK/PD評価系構築と個別化治療への応用","subitem_title_language":"ja"},{"subitem_title":"Construction of PK/PD evaluation system for optimizing treatment using immune checkpoint inhibitors","subitem_title_language":"en"}]},"item_type_id":"8","owner":"15","path":["1692684776404"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2020-11-16"},"publish_date":"2020-11-16","publish_status":"0","recid":"13890","relation_version_is_last":true,"title":["免疫チェックポイント阻害薬のPK/PD評価系構築と個別化治療への応用"],"weko_creator_id":"15","weko_shared_id":-1},"updated":"2023-11-14T00:50:22.718703+00:00"}